# A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

> **NCT03394365** · PHASE3 · RECRUITING · sponsor: **Pierre Fabre Medicament** · enrollment: 115 (estimated)

## Conditions studied

- Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)
- Solid Organ Transplant Complications
- Lymphoproliferative Disorders
- Allogeneic Hematopoietic Cell Transplant
- Stem Cell Transplant Complications

## Interventions

- **BIOLOGICAL:** tabelecleucel

## Key facts

- **NCT ID:** NCT03394365
- **Lead sponsor:** Pierre Fabre Medicament
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-12-29
- **Primary completion:** 2030-05-31
- **Final completion:** 2030-08
- **Target enrollment:** 115 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03394365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03394365, "A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03394365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*